Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Investing.com -- Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE ...

Novo Nordisk is by far the leader in the GLP-1 drug market. The company's pipeline in this area is also very deep. The Danish drugmaker is also looking to diversify its lineup. Novo Nordisk's work ...

from KBP Biosciences for up to $1.3 billion. However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns ($800 million) in relation to the drug after ...

compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of the first Phase 3 trial results for CagriSema in December. Novo Nordisk's (NVO ...

Novo Nordisk is cutting the cost of its blockbuster ... This includes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dose strengths. The list price of the drug before insurance and certain rebates ...